OOIR: Observatory of International Research

Papers

(The median citation count of Diabetes Care is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
About the Artist: Laura Jacobsen, MD	2119
Issues and Events	1593
In This Issue of Diabetes Care	1534
Comment on Maddaloni et al. Bone-Vascular Axis Biomarkers: Enhancing Cardiovascular Risk Management in Type 2 Diabetes	976
Response to Comment on Huh et al. Remnant Cholesterol Is an Independent Predictor of Type 2 Diabetes: A Nationwide Population-Based Cohort Study. Diabetes Care 2023;46:305–312	841
Comment on Gyldenkerne et al. Negative Trend in Peripheral Artery Disease in Incident Type 2 Diabetes in Germany	737
Response to Comments on Maddaloni et al. Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care 2025;48:235–242	715
About the Artist: Abby Gregg	681
Physical Activity Support Can Improve Outcomes in Youth With Type 1 Diabetes	580
Risks of Tight Glucose Control in Older Adults: Time to Focus Beyond Mortality	549
Associations of Dietary Cholesterol Consumption With Incident Diabetes and Cardiovascular Disease: The Role of Genetic Variability in Cholesterol Absorption and Disease Predisposition	441
Predictors of Diabetes Outcomes at 1 Year After Islet Autotransplantation: Data From a Multicenter Cohort Study	438
Comparison of Insulin Titration Strategies for Glycemic Control in Type 2 Diabetes: A Systematic Review and Network Meta-analysis	393
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial	391
Glucagon Prescribing and Costs Among U.S. Adults With Diabetes, 2011–2021	358
Trends in Metformin Use Among Patients With Prediabetes: 2008–2020	337
Data-Driven Phenotypic Clusters of Gestational Diabetes Mellitus and Associations With Risk of Perinatal Complications and Postpartum Diabetes	316
Disparities in Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Prescription and Dispensing in the Israeli Population—A Retrospective Cohort Study	294
Urgent Need for Standardization in CGM Performance Assessment	293
Natural Language Processing for Automated Extraction of Continuous Glucose Monitoring Data	270
Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level	260
Refining the Definition of Stage 1 Type 1 Diabetes: An Ontology-Driven Analysis of the Heterogeneity of Multiple Islet Autoimmunity	258
The Effectiveness of Shared Decision-making for Diabetes Prevention: 24- and 36-Month Results From the Prediabetes Informed Decision and Education (PRIDE) Trial	256
Prevalence of Chronic Kidney Disease in Type 1 Diabetes Among Adults in the U.S.	253
Demographic, Clinical, Management, and Outcome Characteristics of 8,004 Young Children With Type 1 Diabetes	248

The Portfolio Diet and Incident Type 2 Diabetes: Findings From the Women’s Health Initiative Prospective Cohort Study	244
Real-time Continuous Glucose Monitoring in the Intensive Care Unit: The Fifth Vital Sign	241
Proinsulin–to–C-Peptide Ratio as a Marker of β-Cell Function in African American and European American Adults	233
Personalizing Physical Activity for Glucose Control Among Individuals With Type 2 Diabetes: Are We There Yet?	223
Physical Activity for Type 2 Diabetes Prevention: Some Is Better Than None, More Is Better, and Earliest Is Best	223
Plasma Tryptophan-Kynurenine Pathway Metabolites and Risk for Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes	213
Severe Mental Illness and Type 2 Diabetes Outcomes and Complications: A Nationwide Cohort Study	210
About the Artists: John B. Buse, MD, PhD, and Mary Beth Cassely, MSPH	202
Interoceptive Awareness Is Associated With Impaired Awareness of Hypoglycemia in Adults With Type 1 Diabetes	197
Diet-Related Lipidomic Signatures and Changed Type 2 Diabetes Risk in a Randomized Controlled Feeding Study With Mediterranean Diet and Traditional Chinese or Transitional Diets	189
The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)	187
Disclosures: Standards of Care in Diabetes—2025	182
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024	182
Associations Between Glucose Metabolism Measures and Amyloid-β and Tau Load on PET 14 Years Later: Findings From the Framingham Heart Study	177
An Integrated Digital Health Care Platform for Diabetes Management With AI-Based Dietary Management: 48-Week Results From a Randomized Controlled Trial	176
Neuropathic Pain With and Without Diabetic Peripheral Neuropathy in Type 1 Diabetes	176
Issues and Events	175
Issues and Events	173
About the Artist: Giorgio Baldini	170
Is Son Preference a Potential Risk Factor for Diabetes?	170
Disruption to Pattern but No Overall Increase in the Expected Incidence of Pediatric Diabetes During the First Three Years of the COVID-19 Pandemic in Ontario, Canada (March 2020–March 2023)	168
Phenotype and Lifestyle Intervention: Potential for Predicting and Improving Metabolic Outcomes?	167
Rational Pharmacotherapy in Type 2 Diabetes: Danish Data From 2002 to 2020 on Mortality, Diabetes- Related Outcomes, Adverse Events, and Medication Expenses	164
Twenty-Year Temporal Trends in Risk of Ischemic Stroke in Incident Type 2 Diabetes: A Danish Population-Based Cohort Study	161
Management and Outcomes of Severe Hypoglycemia Treated by Emergency Medical Services in the U.S. Upper Midwest	160
Community-Based Peer Support for Diabetes Management: 24-Month Changes Relative to Comparison Communities	149
Plasma Metabolome, Long-term Body Weight Change, and Type 2 Diabetes in U.S. Individuals	149
Quantifying Environmental Waste From Diabetes Devices in the U.S.	149
Diabetic Ketoacidosis at Onset of Type 1 Diabetes and Long-term HbA1c in 7,961 Children and Young Adults in the Australasian Diabetes Data Network	143
Health-Related Quality of Life and Health Utility After Metabolic/Bariatric Surgery Versus Medical/Lifestyle Intervention in Individuals With Type 2 Diabetes and Obesity: The ARMMS-T2D Study	141
Progression of Cerebral Small Vessel Disease Among Neurologically Asymptomatic Middle-Aged Individuals With Type 1 Diabetes	138
Normal-Range Gestational Glucose Challenge Test and Incident Type 2 Diabetes: A Population-Based Cohort Study	136
Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)	133
Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR)	133
Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study	133
Health and Economic Impact and Cost-effectiveness of Produce Prescriptions for Diabetes in 50 U.S. States: A Microsimulation Study	132
Influence of Gestational Diabetes Mellitus on Diabetes Risk and Glycemic Control in a Retrospective Population-Based Cohort	131
Leisure-Time Physical Activity May Attenuate the Impact of Diabetes on Cognitive Decline in Middle-Aged and Older Adults: Findings From the ELSA-Brasil Study	131
Genetic Discovery and Risk Prediction for Type 1 Diabetes in Individuals Without High-Risk HLA-DR3/DR4 Haplotypes	129
Ultra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous	127
Prevalence and Predictors of Household Food Insecurity and Supplemental Nutrition Assistance Program Use in Youth and Young Adults With Diabetes: The SEARCH for Diabetes in Youth Study	124
COVID-19 Vaccination Prior to SARS-CoV-2 Infection Reduced Risk of Subsequent Diabetes Mellitus: A Real-World Investigation Using U.S. Electronic Health Records	122
Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE	120
Estimating Glycemia From HbA1c and CGM: Analysis of Accuracy and Sources of Discrepancy	117
Islet Transplantation Versus Standard of Care for Type 1 Diabetes Complicated by Severe Hypoglycemia From the Collaborative Islet Transplant Registry and the T1D Exchange Registry	117
Inflammatory and Insulinemic Dietary Patterns and Risk of Type 2 Diabetes Among Women With a History of Gestational Diabetes Mellitus: A Prospective Study of 84,174 Person-Years of Follow-up	117
Trends in Racial and Ethnic Disparities in Early Glycemic Control Among Veterans Receiving Care in the Veterans Health Administration, 2008–2019	116
Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study	116
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment	116
Artificial Sweeteners and Risk of Type 2 Diabetes in the Prospective NutriNet-Santé Cohort	115

Challenges in and Opportunities for Individualizing Diabetes Technology: A Position Statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) D	114
Diabetic Retinopathy in Parous Women With and Without Previous Gestational Diabetes Mellitus: A Nationwide Register-Based Cohort Study	113
Response to Comment on Seidu et al. Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review	110
Comment on Hong et al. Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study. Diabetes	108
Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium–Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction	105
Response to Comment on Thai et al. Longitudinal Analysis of Liver Chemistry Trajectories and Risk of Type 2 Diabetes in Children With Metabolic Dysfunction–Associated Steatotic Liver Disease: A Multic	105
Association and Interaction of Genetics and Area-Level Socioeconomic Factors on the Prevalence of Type 2 Diabetes and Obesity	102
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390	102
Maternal Cardiac Changes in Women With Obesity and Gestational Diabetes Mellitus	101
Health Care Utilization Trends Across the Transition Period in a National Cohort of Adolescents and Young Adults With Type 1 Diabetes	101
Association of Metabolic Syndrome With Neuroimaging and Cognitive Outcomes in the UK Biobank	101
Glycemic Control, Cognitive Aging, and Impairment Among Diverse Hispanic/Latino Individuals: Study of Latinos– Investigation of Neurocognitive Aging (Hispanic Community Health Study/Study of Latinos)	100
Physical Activity Is Associated With Improved Glycemic Outcomes in Newly Diagnosed Youth With Type 1 Diabetes: 4T Exercise Program	98
Use of a Dual GIP/GLP-1 Receptor Agonist in HNF1A-MODY and HNF4A-MODY	93
Effect of a Mobile Health Technology–Based Diabetes Education Program on Glucose Control in Patients With Type 2 Diabetes Initiating Premixed Insulin: A Prospective, Multicenter, Observational Study	93
Large Language Model GPT-4 Compared to Endocrinologist Responses on Initial Choice of Glucose-Lowering Medication Under Conditions of Clinical Uncertainty	91
Accuracy and Feasibility of Real-time Continuous Glucose Monitoring in Critically Ill Patients After Abdominal Surgery and Solid Organ Transplantation	89
14. Children and Adolescents: Standards of Care in Diabetes—2023	88
Large-Scale Proteomics Improve Risk Prediction for Type 2 Diabetes	86
Effects of Integrated Care Approaches to Address Co-occurring Depression and Diabetes: A Systematic Review and Meta-analysis	85
The Broader Economic Value of Treatment for Diabetic Macular Edema	85
The Glycemic Impact of Protein Ingestion in People With Type 1 Diabetes	84
Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)	83
Clinical Prediction Models Combining Routine Clinical Measures Have High Accuracy in Identifying Youth-Onset Type 2 Diabetes Defined by Maintained Endogenous Insulin Secretion: The SEARCH for Diabetes	82
Effectiveness of Low Intensity Mental Health Support via a Telehealth Enabled Network (LISTEN) for Adults With Diabetes Distress: A Parallel Group, Pragmatic Randomized Controlled Trial	82
6. Glycemic Targets: Standards of Care in Diabetes—2023	81
Integrative Metabolomics of Targeted and Nontargeted Analyses in T2D Progression	81
Prevalence, Progression, and Modifiable Risk Factors for Diabetic Retinopathy in Youth and Young Adults With Youth-Onset Type 1 and Type 2 Diabetes: The SEARCH for Diabetes in Youth Study	81
Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function	80
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026	79
In This Issue of Diabetes Care	78
8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes–2026	78
Association of Historical Redlining With Gestational Diabetes Mellitus: The Mediating Role of BMI and Area Deprivation Index	76
Prediabetic HbA1c and Cortical Atrophy: Underlying Neurobiology	75
Depressive Symptoms Longitudinally Mediate the Effect of Hyperglycemia on Memory Decline in Type 2 Diabetes	75
Prevalence of Charcot Foot in Subjects With Diabetes: A Nationwide Cohort Study	75
A Special Thanks to the Reviewers of Diabetes Care	74
Issues and Events	74
Comment on Lontchi-Yimagou et al. An Atypical Form of Diabetes Among Individuals With Low BMI. Diabetes Care 2022;45:1428–1437	73
Effect of Low Bolus Frequency on Automated Insulin Delivery System Performance in Youth With Type 1 Diabetes	72
Higher Neighborhood Drivability Is Associated With a Higher Diabetes Risk in Younger Adults: A Population-Based Cohort Study in Toronto, Canada	72
About the Author: Jasmine K.M. Lopez	69
Differential Associations of GAD Antibodies (GADA) and C-Peptide With Insulin Initiation, Glycemic Responses, and Severe Hypoglycemia in Patients Diagnosed With Type 2 Diabetes	67
Associations Between Postdischarge Care and Cognitive Impairment–Related Hospital Readmissions for Ketoacidosis and Severe Hypoglycemia in Adults With Diabetes	66
Historic Residential Redlining and Diabetes: Mediating Pathways and Policy Solutions	66
Trends in Preventive Care Services Among U.S. Adults With Diagnosed Diabetes, 2008–2020	66
Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes	65
Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study	65
Comparison of Serum Creatinine– and Cystatin C–Based eGFR at Baseline and Their Prediction of Incident Moderate Albuminuria in Individuals With Type 1 Diabetes	64
Diabetes Risk Factors and Bone Microarchitecture as Assessed by High-Resolution Peripheral Quantitative Computed Tomography in Adults With Long-standing Type 1 Diabetes	64
From Glucose to Limb Salvage: New Therapeutic Frontiers to Redefine Outcomes in Diabetic Foot Disease	64
Extinguishing the Fire: Treating Pediatric Type 2 Diabetes by Targeting Obesity Treatment	64
Short-Term Metformin Protects Against Glucocorticoid-Induced Toxicity in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial	63
Racial Disparities in Access and Use of Diabetes Technology Among Adult Patients With Type 1 Diabetes in a U.S. Academic Medical Center	63
Are Pediatric Primary Care Providers Ready for Type 1 Diabetes Screening and Monitoring? A Survey From a Large, U.S. Pediatric Network	62
Glucagon-Like Peptide 1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients With Type 2 Diabetes	62
Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes	61
Risk of Phimosis Associated With SGLT2i Versus GLP-1RA: A Danish Cohort Study	61
Carbohydrates-Last Food Order Improves Time in Range and Reduces Glycemic Variability	60
Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the A	60
Age of Diabetes Diagnosis and Lifetime Risk of Dementia: The Atherosclerosis Risk in Communities (ARIC) Study	60
Comment on Liu et al. Low-Carbohydrate Diets of Varying Macronutrient Quality and Risk of Type 2 Diabetes in Three U.S. Prospective Cohort Studies. Diabetes Care 2025;48:2095–2102	60
The Growing Role of Technology in the Care of Older Adults With Diabetes	59
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024	59
Sodium–Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study	57
Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes	56
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)	55
In This Issue of Diabetes Care	55
Use of a Claims-Based Algorithm to Characterize Uptake of Continuous Glucose Monitoring Among Older Adults With Type 1 and Type 2 Diabetes Meeting Medicare Coverage Criteria From 2017 to 2019	54
To Correct or Not to Correct: Lost in Inpatient Translation	54
Diabetes During Pregnancy Among Immigrants in Sweden: A National Cohort Study of All Pregnant Women in Sweden	54
Disparities in Continuous Glucose Monitor Uptake Among Veterans With Diabetes Despite Universal Coverage	53
Is COVID-19 to Blame? Trends of Incidence and Sex Ratio in Youth-Onset Type 2 Diabetes in Germany	52
Health Beliefs Associated With Metformin Use Among Insured Adults With Prediabetes	52
Severe COVID-19 Infection in Type 1 and Type 2 Diabetes During the First Three Waves in Sweden	52
Quantifying Barriers to Diabetic Eye Screening: A Two-Center Study at the University of California	52
Effect of Oral Semaglutide Versus Comparators on Multiple Cardiometabolic Risk Factor Control in Adults With Type 2 Diabetes	52
Painful Diabetic Neuropathy: Myofascial Pain Makes the Difference	51
Associations of Habitual Calcium Supplementation With Risk of Cardiovascular Disease and Mortality in Individuals With and Without Diabetes	50
Association of Water Arsenic With Incident Diabetes in U.S. Adults: The Multi-Ethnic Study of Atherosclerosis and the Strong Heart Study	50

All-Cause Mortality and Cardiovascular and Microvascular Diseases in Latent Autoimmune Diabetes in Adults	50
Redefining Diabetes and Creating Solutions—The Hong Kong Diabetes Register: Kelly West Award Lecture 2025	49
Plasma Metabolite Associations for Risk and Laboratory Measures of Type 2 Diabetes in a Large-Scale Finnish Prospective Cohort	49
Defining Clinically Interpretable Glycemic Profiles Using Continuous Glucose Monitoring in Type 2 Diabetes	48
New-Onset Fulminant Type 1 Diabetes After SARS-CoV-2 Infection	48
MiniMed 780G Advanced Hybrid Closed-Loop System Use During Days Without User-Initiated Boluses	48
Effects of Modern Glucose Monitoring and Insulin Delivery Technologies on Patient-Reported Outcomes and Experiences in Individuals With Type 1 Diabetes: A Systematic Review and Meta-analysis	48
High Prevalence of Prediabetes Among Asian and Pacific Islander Adolescents With Overweight or Obesity in a Primary Care Population	48
Changes in Type 2 Diabetes Medications Among Primary Care Patients After California’s 2022 Medicaid Expansion	48
17. Diabetes Advocacy: Standards of Care in Diabetes—2024	47
Transition of BMI Status From Childhood to Adulthood and Cardiovascular-Kidney-Metabolic Syndrome in Midlife: A 36-Year Cohort Study	47
Sleep Extension Improves Sleep Health but Not Insulin Sensitivity in People With Overweight or Obesity Who Maintain Habitual Short Sleep Schedules	47
Association Between Age at Diabetes Diagnosis and Subsequent Incidence of Cancer: A Longitudinal Population-Based Cohort	47
Diabetes Stigma and Psychosocial Outcomes in Adolescents and Young Adults: The SEARCH for Diabetes in Youth Study	46
Erratum. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care 2024;47(Suppl. 1):S158–S178	46
Flexor Tendon Tenotomy Treatment of the Diabetic Foot: A Multicenter Randomized Controlled Trial	46
Is the Current Lifestyle Modification Approach to Diabetes Prevention in the U.S. a Success?	45
Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infar	45
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023	45
Disparities Between Teleretinal Imaging Findings and Patient-Reported Diabetic Retinopathy Status and Follow-up Eye Care Interval: A 10-Year Prospective Study	45
Association of Insulin Resistance With Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: Systematic Review and Meta-analysis	45
Summary of Revisions: Standards of Care in Diabetes—2025	44
12. Retinopathy, Neuropathy, and Foot Care:Standards of Care in Diabetes—2023	44
The NIDDK Takes on the Complications of Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study	44
Racial and Ethnic Differences Between Waist Circumference and BMI in Identifying Obesity	44
About the Artist: Kathy McNamara	43
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026	43
Continuous Glucose Monitoring and Mortality Risk Among U.S. Veterans Receiving Dialysis With Diabetes	43
Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials	43
Global Prevalence of Prediabetes	43
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2024	43
Response to Comment on Kofod et al. The Association Between Hemoglobin A1c and Complications Among Individuals With Diabetes and Severe Chronic Kidney Disease. Diabetes Care 2025;48:1400–1409	42
Comment on Agbaje et al. Persistent Hyperglycemia and Insulin Resistance With the Risk of Worsening Cardiac Damage in Adolescents: A 7-Year Longitudinal Study of the ALSPAC Birth Cohort. Diabetes Care	42
Response to Comment on Galvez-Fernandez et al. Urinary Zinc and Incident Type 2 Diabetes: Prospective Evidence From the Strong Heart Study. Diabetes Care 2022;45:2561–2569	42
Risk of Infection in Older Adults With Type 2 Diabetes With Relaxed Glycemic Control	42
About the Artist: Appleton	42
About the Editor: Cheryl A.M. Anderson, PhD, MPH, MS: Promoting Health Equity Through Nutrition	42
Issues and Events	42
Association of Insulin Resistance and Insulin Secretion Indices and Glucose Metrics From Continuous Glucose Monitoring in People With Obesity	42
Response to Comment on Kaminski et al. Assessment of Glycemic Control by Continuous Glucose Monitoring, Hemoglobin A1c, Fructosamine, and Glycated Albumin in Patients With End-Stage Kidney Disease and	42
Issues and Events	42
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease	41
Earlier Age at Type 2 Diabetes Diagnosis Is Associated With Increased Genetic Risk of Cardiovascular Disease	41
Comment on Abdelgani et al. Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes. Diabetes Care 2024;47:668–675	40
Association of Continuous Glucose Monitoring Metrics With Pregnancy Outcomes in Patients With Preexisting Diabetes	40
Real-world Accuracy of CGM in Inpatient Critical and Noncritical Care Settings at a Safety-Net Hospital	40
Unravelling Diabetes Endotypes and Associated Pathophysiology for Precision Medicine in Diabetes: Ready for Prime Time?	39
Declining Incidence Rates of Distal Symmetric Polyneuropathy in People With Type 1 and Type 2 Diabetes in Denmark, With Indications of Distinct Patterns in Type 1 Diabetes	39
Hunting for Progressive NAFLD in Type 2 Diabetes: Do Not Trust Liver Enzymes!	38
Ten Years of Improving Glycemic Control in Pediatric Diabetes Care: Data From the Norwegian Childhood Diabetes Registry	38
Issues and Events	38
Range of Risk Factor Levels, Risk Control, and Temporal Trends for Nephropathy and End-stage Kidney Disease in Patients With Type 1 and Type 2 Diabetes	38
Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study	37
Impact of Type 2 Diabetes and Glycated Hemoglobin Levels Within the Recommended Target Range on Mortality in Older Adults With Cognitive Impairment Receiving Care at a Memory Clinic: NCGG-STORIES	37
Associations of General Adiposity, Abdominal Adiposity and Their Changes With Fracture Risk in Chinese Individuals With Type 2 Diabetes: A Population-Based Cohort Study in Hong Kong	37
The Association Between Hemoglobin A1c and Complications Among Individuals With Diabetes and Severe Chronic Kidney Disease	37
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial	37
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial	37
Historic Residential Redlining and Present-day Diabetes Mortality and Years of Life Lost: The Persistence of Structural Racism	37
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024	37
Association of Metabolic Syndrome With Incident Dementia: Role of Number and Age at Measurement of Components in a 28-Year Follow-up of the Whitehall II Cohort Study	37
β-Cell Function Derived From Routine Clinical Measures Reports and Predicts Treatment Response to Immunotherapy in Recent-Onset Type 1 Diabetes	36
Continuous Glucose Monitoring Metrics and Birth Weight: Informing Management of Type 1 Diabetes Throughout Pregnancy	36
Dipeptidyl Peptidase 4 Inhibitors and Gallbladder or Biliary Diseases: Data From the U.S. Food and Drug Administration Adverse Event Reporting System	36
The National Clinical Care Commission Report to Congress: Recommendations to Better Leverage Federal Policies and Programs to Prevent and Control Diabetes	36
5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2025	35
Safety and Efficacy of Sustained Automated Insulin Delivery Compared With Sensor and Pump Therapy in Adults With Type 1 Diabetes at High Risk for Hypoglycemia: A Randomized Controlled Trial	35
Examining the Acute Glycemic Effects of Different Types of Structured Exercise Sessions in Type 1 Diabetes in a Real-World Setting: The Type 1 Diabetes and Exercise Initiative (T1DEXI)	35
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity	35
Introduction and Methodology: Standards of Care in Diabetes—2023	35
Longitudinal Analysis of Liver Chemistry Trajectories and Risk of Type 2 Diabetes in Children With Metabolic Dysfunction–Associated Steatotic Liver Disease: A Multicenter Cohort Study	34
Symptoms of Anxiety and Depression Are Independently Associated With Impaired Awareness of Hypoglycemia in Type 1 Diabetes	34
The Use of Point-of-Care Bacterial Autofluorescence Imaging in the Management of Diabetic Foot Ulcers: A Pilot Randomized Controlled Trial	34
Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes	34
About the Artist: Anna Ferrannini	33
Comment on Wong et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression	33
Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005–1013	33
Erratum. A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting. Diabetes Care 2024;47	33
Incidence of Type 1 Diabetes in Relation to Exposure to Rotavirus Infections in Pre- and Postvaccine Birth Cohorts in Finland	33
Evaluation of the Clinical Impact of Dapagliflozin Discontinuation as Adjunctive Therapy for Patients With Type 1 Diabetes After Indication Withdrawal: A Two-Center Retrospective Study	33
Issues and Events	33
The Glucose Management Indicator: Time to Change Course? Diabetes Care 2024;47:906–914	33
NIDDK at 75 Years of Age: Great Triumphs but Concerns for Its Longevity	33
Mortality in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)	32
Time-to-Event Genome-Wide Association Study for Incident Cardiovascular Disease in People With Type 2 Diabetes	32
Incidence, Severity, and Presentation of Type 2 Diabetes in Youth During the First and Second Year of the COVID-19 Pandemic	32
An Examination of Whether Diabetes Control and Treatments Are Associated With Change in Frailty Index Across 8 Years: An Ancillary Exploratory Study From the Action for Health in Diabetes (Look AHEAD)	32
About the Artist: Eleonora Nigro, MSc	32
Managing Impending Nonsevere Hypoglycemia With Oral Carbohydrates in Type 1 Diabetes: The REVERSIBLE Trial	32
Proteomic Predictors of Incident Diabetes: Results From the Atherosclerosis Risk in Communities (ARIC) Study	32
HLA Class II (DR, DQ, DP) Genes Were Separately Associated With the Progression From Seroconversion to Onset of Type 1 Diabetes Among Participants in Two Diabetes Prevention Trials (DPT-	32
Symptoms of Autonomic Nervous System Dysregulation and Diabetes Distress in Adults With Type 1 and Type 2 Diabetes	32
Estimated Optimal Individualized Diabetes Risk Prediction From Preventive Interventions in the U.S. General Population	32
Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a	31
Sociodemographic, Clinical, and Psychosocial Predictors of Short- and Long-term Study Retention in the Diabetes Prevention Program (DPP) Outcomes Study (DPPOS)	31